

## **I. OVERVIEW OF THE FUNDING OPPORTUNITY**

**Broad Agency Announcement for Extramural Research (Program Specific) for the  
Department of Defense**

**Defense Health Program**

**Congressionally Directed Medical Research Programs**

**Combat Readiness – Medical Research Program**

**Rapid Development and Translational Research Award**

**Announcement Type: Initial**

**Funding Opportunity Number: W81XWH-19-S-CRRP**

**Catalog of Federal Domestic Assistance Number: 12.420 Military Medical  
Research and Development**

### **SUBMISSION AND REVIEW DATES AND TIMES**

- **Pre-Application (Letter of Intent) Submission Deadline:** 5:00 p.m. Eastern time (ET), October 23, 2019
- **Proposal/Application Submission Deadline:** 11:59 p.m. ET, November 13, 2019
- **End of Proposal/Application Verification Period:** 5:00 p.m. ET, November 18, 2019
- **Peer Review:** January 2020
- **Programmatic Review:** April 2020

*This Broad Agency Announcement must be read in conjunction with the General Submission Instructions, which are available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”*

## TABLE OF CONTENTS

<b>I. OVERVIEW OF THE FUNDING OPPORTUNITY.....</b>	<b>1</b>
<b>II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY.....</b>	<b>3</b>
II.A. Program Description.....	3
II.A.1. FY19 CRRP RDTRA Focus Areas .....	4
II.A.2. Award Background.....	5
II.B. Award Information .....	6
II.C. Eligibility Information.....	11
II.C.1. Eligible Applicants .....	11
II.C.2. Cost Sharing.....	12
II.C.3. Other .....	13
II.D. Proposal/Application and Submission Information .....	14
II.D.1. Address to Request Proposal/Application Package.....	14
II.D.2. Content and Form of the Proposal/Application Submission .....	14
II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM) .....	31
II.D.4. Submission Dates and Times.....	31
II.D.5. Intergovernmental Review .....	32
II.D.6. Funding Restrictions.....	32
II.D.7. Other Submission Requirements .....	33
II.E. Proposal/Application Review Information .....	33
II.E.1. Criteria .....	33
II.E.2. Proposal/Application Review and Selection Process .....	37
II.E.3. Integrity and Performance Information.....	37
II.E.4. Anticipated Announcement and Federal Award Dates.....	38
II.F. Award Administration Information .....	38
II.F.1. Award Notices.....	38
II.F.2. Administrative and National Policy Requirements.....	38
II.F.3. Reporting Requirements.....	39
II.G. Agency Contacts.....	39
II.G.1. CDMRP Help Desk .....	39
II.G.2. Grants.gov Contact Center .....	40
II.H. Other Information.....	40
II.H.1. Administrative Actions.....	40
II.H.2. Proposal/Application Submission Checklist .....	43
<b>APPENDIX I: ACRONYM LIST.....</b>	<b>45</b>
<b>APPENDIX II: DOD AND VA WEBSITES .....</b>	<b>47</b>
<b>APPENDIX III: SAMPLE FITBIR CONSENT LANGUAGE.....</b>	<b>49</b>
<b>APPENDIX IV: TECHNOLOGY READINESS LEVELS AND KNOWLEDGE READINESS LEVELS.....</b>	<b>52</b>

## II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

**Proposal/application submission by extramural organizations through Grants.gov requires use of the Workspace interface, which separates the application package into individual forms. Applicants must create a Workspace in Grants.gov, complete the required forms, and submit their proposal/application Workspace package.**

This Funding Opportunity Announcement is a Broad Agency Announcement (BAA) through the Fiscal Year 2019 (FY19) Combat Readiness – Medical Research Program (CRRP) for the Rapid Development and Translational Research Award (RDTRA). For the remainder of the announcement, this BAA will be referenced as RDTRA. Specific submission information and additional administrative requirements can be found in the document titled “General Submission Instructions,” available in Grants.gov along with this BAA.

**This BAA for CRRP is intended to solicit extramural research and development ideas** using the authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). This BAA is issued under the provisions of the Competition in Contracting Act (CICA) of 1984 (Public Law 98-369), as implemented in Federal Acquisition Regulation (FAR) 6.102(d)(2) and 35.016 and in Department of Defense Grant and Agreement Regulations (DoDGARs) 22.315. In accordance with FAR 35.016, projects funded under this BAA must be for *applied and clinical research (excluding clinical trials)* not related to the development of a specific system or hardware procurement. Research and development funded through this BAA is intended and expected to benefit and inform both military and civilian medical practice and knowledge.

***This BAA is intended for extramural applicants only. For definitions and additional information, see [Section II.C.1, Eligible Applicants](#).***

### II.A. Program Description

Proposal/applications to the FY19 CRRP RDTRA are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by 10 USC 2358. As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The U.S. Army Medical Research and Development Command (USAMRDC) Congressionally Directed Medical Research Programs (CDMRP) is the execution management agent for this BAA.

The CRRP was initiated by Congress in FY19 with an appropriation of \$15 million (M) to pursue military-relevant advanced technology and therapeutic research related to forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Warfighters in current and future battlefield settings. The Congressional language for the CRRP encompasses research that would enable the Warfighter to better respond to serious injury, as well as solutions to mitigate the long-term effects of battlefield trauma, including: (1) enhancing battlefield diagnostics for neurological injuries and hemorrhage;

(2) integrated wound care and tissue regeneration therapies; (3) environmental and wearable sensors, combined with advanced computing, for surveillance and monitoring of chemical and biological threat exposures; (4) telemedicine applications for battlefield medicine, to allow for better collection, integration, and transfer of patient data from battlefield medical units through transport and treatment; (5) chemical and biological exposure, countermeasures, and management strategies; and (6) solutions for infectious disease management, including sepsis.

The CRRP vision is to deliver high-impact medical solutions throughout the continuum of care to increase survivability and readiness of the Warfighter in diverse operational settings. Per the program's mission statement, the CRRP seeks to develop innovative solutions to increase medical readiness, mitigate fatalities, optimally treat life-threatening injuries, and promote positive long-term outcomes. Innovations developed by CRRP-supported research may be applied proactively as a way to establish medical readiness ahead of deployment, in-theater at the point of injury or during periods of prolonged care, or during transport/en route care within and from theater. These solutions will not only help to minimize the morbidity and mortality of combat-related injuries sustained by the Warfighter, they will also often translate to civilian care.

### **II.A.1. FY19 CRRP RDTRA Focus Areas**

The Focus Areas were defined from research priorities described in the Congressional language for the CRRP in FY19. These Focus Areas broadly describe current priorities to improve readiness for delivering frontline care in combat situations and for delivering medical damage control capability, assets, and lifesaving interventions during prolonged and en route care in austere and combat environments, including the acute and early management of combat-related trauma at the point of injury. To meet the intent of the award mechanism, proposals/applications submitted to the FY19 CRRP RDTRA ***must address at least one of the FY19 CRRP RDTRA Focus Areas*** listed below.

- Scalable solutions for wound care that can address prevention of bleeding and infection, delivery of therapeutics, and promotion of healing
- Decision-support solutions, such as algorithms, artificial intelligence, deep learning, telemedicine, etc. for triage and management of severely injured Warfighters, to include management and monitoring of:
  - Acute pain, to include non-opioid solutions
  - Hemorrhage and resuscitation (e.g., airway management, control of bleeding, sedation, etc.)
  - Multi-casualty events when delayed evacuation exceeds available capability and/or capacity, in order to extend or enhance provider capabilities
- Solutions that address hemorrhage control, including:
  - Non-compressible torso hemorrhage
  - Alternatives to optimize logistics and administration of blood products to the Warfighter

- Wearable sensors with multiple capabilities to identify and monitor medical management of injuries and/or exposures, such as:
  - Environmental exposures
  - Onset of infection, including sepsis
  - Physiological status and stress monitoring tools (heart rate, blood pressure, respiration)
  - Neurological injury
  - Point-of-care imaging in prolonged field care

Selection of the appropriate FY19 CRRP RDTRA Focus Area is the responsibility of the applicant. Additional concurrent research approaches that address mitigation of long-term physical and psychological complications that occur from management of trauma pain and trauma care, as well as treatments for sepsis and new therapies for multidrug-resistant pathogens, and injuries incurred outside the battlefield are *encouraged, but not required*.

## **II.A.2. Award Background**

Treating and returning military personnel to duty, which maintains Force strength and lethality, has always been a primary mission of the Services. In the wars in Iraq and Afghanistan, the U.S. military achieved the highest rate of survival from battlefield injuries in history. The wounded-to-killed ratio more than doubled, from 4:1 during last century’s world wars, to 10:1 today.<sup>1</sup> Substantial credit for this achievement is due to a 2009 Congressional mandate that stated wounded Warfighters should be provided with lifesaving care within 60 minutes of injury, a timespan that is referred to as the “golden hour.” At the time, the battlefield had numerous forward surgical teams, combat support hospitals, and medevac assets from all Services. The available infrastructure mitigated the need for prolonged field care and enabled transportation of casualties to a damage control capability in traditional Role of Care 2 or Role of Care 3 environments where “golden hour” medical assets and interventions were available.

Recent reports indicate that the concept of the “golden hour” may not be feasible for Warfighters in future conflict environments, and there is a need to efficiently bring acute, lifesaving care to the point of injury and provide prolonged field care (greater than 72 hours) where necessary. Future combat scenarios may require Service members to fight conventional wars against peer or near-peer adversaries in multi-domain operations (MDO) where evacuation capabilities are delayed or unavailable. The MDO concept requires that the military be prepared to conduct operations in all potential contested domains (land, air, sea, cyber, and space) with potential adversaries that have the ability to limit or deter access to those domains. Considerations of future battlefields include maneuvering across expanded battlespaces in the competitive and armed conflict stages, as well as medical and casualty care support for dispersed and sometimes isolated Forces under difficult conditions, such as dense urban, subterranean, maritime, high-

---

<sup>1</sup>Kotwal RS, Howard JT, Orman JA, et al. 2016. The effect of a golden hour policy on the morbidity and mortality of combat casualties. *JAMA Surgery* 151(1):15-24.

altitude, dust storm, and extreme environments. While access to clinic-based providers under such conditions may not be feasible, utilization of clinical decision support tools, to include those integrated with biological sensors capable of physiological monitoring, and other automated technologies may inform on continued Force readiness and availability in combat environments and assist Warfighters in providing additional lifesaving care where clinical capabilities are limited. In addition, MDO casualty care must address not only the scope of these challenges, but also the scale of casualties projected. Mass casualty events that overwhelm immediately available medical capabilities, to include personnel, supplies, and/or equipment, present a significant obstacle to providing damage control interventions closer to the point of need.

The “golden hour” and MDO doctrines are not specific to the military, but have broad applications that extend to civilian care. The “golden hour” concept defines a period of time following a traumatic injury during which there is the highest likelihood that prompt medical and surgical treatment will prevent death. Natural disasters, explosive events, accidents, and acts of violence can lead to sudden large numbers of casualties and complex injuries similar to those experienced on the battlefield. Civilian communities in areas with limited or distant access to hospital-based care may also face challenges in providing acute, lifesaving care to injured individuals. The possibility of urban warfare presents new challenges and considerations for civilian mass casualty events, such as simultaneous military and civilian trauma care operations, with impacts on the role of first-responders and emergency department personnel or delivering care under conditions of disrupted communications. This shift requires a reassessment of existing approaches and innovation of new approaches and tools for extending trauma care to maximize survivability in complex environments.

## **II.B. Award Information**

The CRRP seeks to enhance medical capabilities at the point of greatest need in order to save the most lives in future combat scenarios, which may be complicated by limited resources, austere conditions, and/or mass casualty events. The intent of the FY19 CRRP RDTRA is to support research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines. Applicants may leverage existing resources in translational research to address high-impact research ideas or unmet needs in delivering lifesaving care to the Warfighter during prolonged and en route care in austere and combat environments. Research of interest may include knowledge products, “knowledge resulting from research with the potential to improve individual or public health,”<sup>2</sup> and solutions that can accelerate the introduction of military-relevant health products or technologies into clinical and/or operational use. For this award mechanism, the definition of “leveraging” is as follows: An investigator basing a research project on existing resources in order to amplify potential gains in knowledge or accelerate technical maturity. Projects should consider the varied expertise levels of the medical providers and the possible diverse environmental conditions in combat situations. Proposal/application submissions are encouraged to include characteristics relevant to military use in non-hospital settings in theater, but submissions that

---

<sup>2</sup>Engel CC, Silbergliitt R, Chow BG, et al. 2019. Development of a Knowledge Readiness Level framework for medical research. Santa Monica, CA: RAND Corporation, RR-2127-OSD.  
[https://www.rand.org/pubs/research\\_reports/RR2127.html](https://www.rand.org/pubs/research_reports/RR2127.html).

propose solutions to advance civilian trauma care are not precluded, since civilian trauma care frequently informs and influences trauma care in the military, and vice versa.

Preclinical research, including animal studies, that is already supported by substantial preliminary or published data and strongly validates clinical translation is appropriate for this award mechanism.

***Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity.*** A clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.

The anticipated direct costs budgeted for the entire period of performance for an FY19 CRRP RDTRA will not exceed **\$1,500,000**. Refer to [Section II.D.5, Funding Restrictions](#), for detailed funding information.

***The CDMRP expects to allot approximately \$13M to fund approximately five to six RDTRA proposal/applications. Funding of proposal/applications received is contingent upon the availability of Federal funds for this program as well as the number of proposal/applications received, the quality and merit of the proposal/applications as evaluated by scientific and programmatic review, and the requirements of the Government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY19 funding opportunity will be funded with FY19 funds, which will expire for use on September 30, 2025.***

Awards will be made no later than September 30, 2020. For additional information refer to [Section II.F.1, Federal Award Notices](#).

The USAMRDC executes its extramural research program primarily through the awarding of contracts and assistance agreements (grants and cooperative agreements). The type of instrument used to reflect the business relationship between the organization and the Government is at the discretion of the Government, in accordance with the Federal Grant and Cooperative Agreement Act of 1977, as amended, 31 USC 6301-6308, which provides the legal criteria to select a procurement contract or an assistance agreement. An assistance agreement (grant or cooperative agreement) is appropriate when the Federal Government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States, instead of acquiring property or service for the direct benefit and use of the U.S. Government. An assistance agreement can take the form of a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304).

Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305) and the award will identify the specific

substantial involvement. Substantial involvement may include collaboration, participation, or intervention in the research to be performed under the award.

A contract is required when the principal purpose of the instrument is to acquire property or services for the direct benefit or use of the U.S. Government.

The award type, along with the start date, will be determined during the negotiation process.

Please see Appendix 2, Section E of the General Submission Instructions for more information.

**This BAA may *not* be used to support fundamental basic research:** For this BAA, basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind.

**Research Involving a U.S. Food and Drug Administration (FDA)-Regulated Drug, Biologic, or Device:** If the study proposed involves the use of a drug or biologic that has not been approved by the FDA for the proposed investigational use, evidence is required that an Investigational New Drug (IND) application that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) *has been submitted or will be submitted to the FDA within 60 days of award*. If the investigational product is a device, evidence is required that an Investigational Device Exemption (IDE) application, that meets all requirements under 21 CFR 812, *has been submitted or will be submitted to the FDA within 60 days of award*.. The Government reserves the right to withdraw funding if the IND or IDE application has not been submitted to the FDA within 60 days of the Department of Defense (DoD) award date or if the documented application status of the IND or IDE has not been obtained within 12 months of the award date.

**Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers:** All DoD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC Office of Research Protections (ORP), Human Research Protection Office (HRPO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is *not* required. The HRPO is mandated to comply with specific laws and requirements governing all research involving human anatomical substances, human subjects, or human cadavers that is supported by the DoD. These laws and requirements will necessitate information in addition to that supplied to the IRB/EC. *Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes*. Additional time for regulatory reviews may be needed for clinical studies taking place in international settings. When possible, protocols should be written for research with human subjects and/or human anatomical substances that are specific to the DoD-supported effort outlined in the submitted proposal/application as a stand-alone study. Submission to HRPO of protocols involving more than the scope of work in the DoD-funded award will require HRPO review of the entire protocol (DoD and non-DoD funded). DoD human subjects protection requirements may be applied to non-DoD funded work and necessitate extensive revisions to the protocol. Proposals/applications that involve recruitment of human subjects must indicate the quarterly



enrollment targets across all sites in [Attachment 5: Statement of Work \(SOW\)](#). Successful applicants will work with USAMRAA to establish milestones for human subjects recruitment. Continued support for the project will be based upon satisfactory progress in meeting the established milestones. Refer to the General Submission Instructions, Appendix 1, and the Human Subject Resource Document available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) for additional information.

**Rigor of Experimental Design:** All projects should adhere to accepted standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. Core standards are described in Landis, S.C., et al., A call for transparent reporting to optimize the predictive value of preclinical research, *Nature* 2012, 490:187-191 ([www.nature.com/nature/journal/v490/n7419/full/nature11556.html](http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html)). While these standards were written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in research and should be applied consistently across translational studies. Projects that include research on animal models are required to submit [Attachment 7: Animal Research Plan](#), as part of the proposal/application package to describe how these standards will be addressed. Applicants should consult the ARRIVE (Animal Research: Reporting *In Vivo* Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines can be found at [https://www.elsevier.com/\\_data/promis/misc/622936arrive\\_guidelines.pdf](https://www.elsevier.com/_data/promis/misc/622936arrive_guidelines.pdf).

**Use of DoD or Department of Veterans Affairs (VA) Resources:** If the proposed research involves access to active duty military patient populations and/or DoD resources or databases, the proposal/application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Access to target active duty military patient population(s) and/or DoD resource(s) or database(s) should be confirmed by including a letter of support, signed by the lowest-ranking person with approval authority.

If the proposed research involves access to VA patient populations, VA study resources and databases, and/or VA research space and equipment, VA Principal Investigators (PIs) must have a plan for obtaining and maintaining access throughout the proposed research. Access to VA patients, resources, and/or VA research space should be confirmed by including a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief. If appropriate, the proposal/application should identify the VA-affiliated non-profit corporation (NPC) as the applicant institution for VA PIs. If the VA NPC is not identified as the applicant institution for administering the funds, the proposal/application should include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

Access to certain DoD or VA patient populations, resources, or databases may only be obtained by collaboration with a DoD or VA investigator who has a substantial role in the research and may not be available to a non-DoD or non-VA investigator if the resource is restricted to DoD or VA personnel. Investigators should be aware of which resources are available to them if the proposed research involves a non-DoD or non-VA investigator collaborating with the DoD

and/or VA. If access cannot be confirmed at the time of proposal/application submission, the Government reserves the right to withdraw or revoke funding until the PI has demonstrated support for and access to the relevant population(s) and/or resource(s). Refer to [Section II.D.2.b.ii, Full Proposal/Application Submission Components](#), for detailed information.

**Research Involving Animals:** All DoD-funded research involving new and ongoing research with animals must be reviewed and approved by the USAMRDC ORP Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is *not* required. Specific documents relating to the use of animals in the proposed research will be requested **if the proposal/application is selected for funding**. The ACURO must review and approve all animal use prior to the start of working with animals, including amendments to ongoing projects. PIs must submit the institutional animal use protocol, IACUC approval of that protocol, and a version of the animal use appendix titled, “Research Involving Animals.” ***Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies.*** Refer to the General Submission Instructions, Appendix 1, for additional information.

**Federal Interagency Traumatic Brain Injury Research (FITBIR) Data Sharing:** The DoD requires that awardees make traumatic brain injury (TBI) research data generated by this award mechanism available to the research community through the FITBIR Informatics System. The FITBIR Informatics System is a free resource designed to accelerate research progress by allowing the storage, re-analysis, integration, and rigorous comparison of multiple datasets. Currently FITBIR eligible research include all studies generating prospectively collected human TBI subject data (e.g., clinical, demographic, phenotypic, imaging, and genomic). Data reporting to FITBIR is an opportunity for investigators to facilitate their own research and to collaborate with others engaged in similar research. While there is no direct charge to users of the FITBIR Informatics System, a project estimation tool (<https://fitbir.nih.gov/jsp/contribute/fitbir-costs.jsp>) is available to help estimate costs and manpower needs that may be associated with data submission. FITBIR guidance and policies, as well as the considerable advantages of FITBIR participation to the researcher, are detailed at <https://fitbir.nih.gov>.

In order to share data with FITBIR, three elements must be included in the proposed research:

1. Updated informed consent language that includes FITBIR data sharing. Sample consent language is included in [Appendix III](#).
2. Global Unique Identifier (GUID): FITBIR encourages collaboration between laboratories, as well as interconnectivity with other informatics platforms. Such community-wide sharing requires common data definitions and standards. FITBIR allows for de-identification and storage of data (medical imaging clinical assessment, environmental and behavioral history, etc.) of various types (text, numeric, image, time series, etc.). Use of FITBIR’s GUID system facilitates repeated and multi-user access to data without the need to personally identify data sources. In order to generate a GUID for a subject, the following personally identifiable information (PII) ***must be collected in the proposed research:***

- Complete legal given (first) name of subject at birth
- Complete legal additional name of subject at birth (if subject has a middle name)
- Complete legal family (last) name of subject at birth
- Day of birth
- Month of birth
- Year of birth
- Name of city/municipality in which subject was born
- Country of birth

*Note that this PII is never sent to the FITBIR system. PII cannot be extracted from the GUID. Information on GUID compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations can be found at <https://fitbir.nih.gov/content/global-unique-identifier>.*

3. Common Data Elements (CDEs): Research data elements must be reported using the National Institute of Neurological Disorders and Stroke (NINDS) TBI CDEs or entered into the FITBIR data dictionary as new, unique data elements (UDEs). For the most current version of the NINDS TBI CDEs, go to <https://www.commondataelements.ninds.nih.gov>. Assistance will be available to help the researchers map their study variables to specific CDEs and ensure the formats of the CDEs collected are compatible with the FITBIR Informatics System. Use of the TBI CDEs is required wherever possible in an effort to create standardized definitions and guidelines about the kinds of data to collect and the data collection methods that should be used in clinical studies of TBI. ***Use of UDEs is strongly discouraged and subject to program approval.***

The CDMRP intends that information, data, and research resources generated under awards funded by this BAA be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Submission Instructions, Appendix 2, Section L.

## **II.C. Eligibility Information**

### **II.C.1. Eligible Applicants**

#### **II.C.1.a. Organization: All organizations, including international organizations, are eligible to apply.**

Awards are made to organizations only, not to individuals. Organizations eligible to apply include national, international, for-profit, non-profit, public, and private organizations. Refer to the General Submission Instructions, Appendix 3, for general eligibility information.

**NOTE:** In accordance with FAR 35.017, Federally Funded Research and Development Centers (FFRDCs) are not eligible to directly receive awards under this BAA. However, teaming arrangements between FFRDCs and eligible organizations are allowed so long as they are permitted under the sponsoring agreement between the Federal Government and the specific FFRDC.

The USAMRDC is committed to supporting small businesses. Small business, Veteran-owned small business, Service-disabled Veteran-owned small business, Historically Underutilized Business Zone (HUBZone) small business, small disadvantaged business, and woman-owned small business concerns must be given the maximum practical opportunity to participate through subawards on research proposals/applications submitted through this BAA.

**Government Agencies Within the United States:** Local, state, and Federal Government agencies are eligible to the extent that proposals/applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their proposals/applications do not overlap with their internal programs.

**Proposals/applications for this BAA may only be submitted by extramural organizations.** Submissions from intramural DoD organizations to this BAA will be withdrawn.

**Extramural Organization:** An eligible non-DoD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, other Federal Government organization other than the DoD, and research institutes.

**Intramural DoD Organization:** A DoD laboratory, DoD military treatment facility, and/or DoD activity embedded within a civilian medical center.

**Note:** Proposals/applications from an intramural DoD organization or from an extramural Federal Government organization may be submitted to Grants.gov through a research foundation. ***It is also permissible, for an intramural investigator to be named as a collaborator on a proposal/application submitted through an extramural organization. In this case, the proposal/application must include a letter from the collaborator's Commander or Commanding Officer at the intramural organization that authorizes the collaborator's involvement.*** For more information, refer to the General Submission Instructions, Section III.

**II.C.1.b. Principal Investigator:** Independent investigators at all academic levels (or equivalent) are eligible to be named by the organization as the PI in the proposal/application.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at <https://orcid.org/>.

## **II.C.2. Cost Sharing**

Cost sharing/matching is not required under this BAA.

### **II.C.3. Other**

Organizations must be able to access **.gov** and **.mil** websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

There are no limitations on the number of proposals/applications for which an investigator may be named as a PI.

***Use of the System for Award Management (SAM) and the Federal Awardee Performance and Integrity Information System (FAPIS):*** To protect the public interest, the Federal Government ensures the integrity of Federal programs by striving to conduct business only with responsible organizations. The USAMRDC uses the “Exclusions” within the Performance Information functional area of the SAM and data from FAPIS, a component within SAM, to verify that an organization is eligible to receive Federal awards. More information about SAM and FAPIS is available at <https://sam.gov/>. Refer to the General Submission Instructions, Appendix 3, for additional information.

***Conflicts of Interest:*** All awards must be free of conflicts of interest (COIs) that could bias the research results. Prior to award of a contract, applicants will be required to disclose all potential or actual COIs along with a plan to manage them. An award may not be made if it is determined by the USAMRAA Contracting Officer that COIs cannot be adequately managed. Refer to the General Submission Instructions, Appendix 3, for additional information.

***Review of Risk:*** The following areas may be reviewed in evaluating the risk posed by an applicant: financial stability; quality of management systems and operational controls; history of performance; reports and findings from audits; ability to effectively implement statutory, regulatory, or other requirements imposed on non-Federal entities; degree of institutional support; integrity; adequacy of facilities; and conformance with safety and environmental.

For general information on required qualifications for award recipients, refer to the General Submission Instructions, Appendix 3.

***Subcontracting Plan:*** If the resultant award is a contract that exceeds \$700,000 and the offeror is other than a small business, the contractor will be required to submit a subcontracting plan for small business and small disadvantaged business concerns, in accordance with FAR 19.704, Army Federal Acquisition Regulation Supplement, Subpart 5119.704 (AFARS 5119.704), and Defense Federal Acquisition Regulation Supplement, Subpart 219.704 (DFARS 219.704). A mutually agreeable plan will be developed during the award negotiation process and incorporated as part of the resultant contract.

In addition to other information provided herein, by submitting a proposal/application and accepting an award, the organization is: (1) certifying that the applicants’ credentials have been examined and (2) verifying that the applicants are qualified to conduct the proposed study and to use humans as research subjects, if proposed. Applicants include all individuals, regardless of ethnicity, nationality, or citizenship status, who are employed by, or affiliated with, an eligible organization.

Refer to [Section II.H.2, Administrative Actions](#), for a list of administrative actions that may be taken if a pre-application (Letter of Intent [LOI]) or proposal/application does not meet the administrative, eligibility, or ethical requirements defined in this BAA.

## **II.D. Proposal/Application and Submission Information**

### **II.D.1. Address to Request Proposal/Application Package**

To obtain the complete Grants.gov proposal/application package (hereinafter, submission package), including all required forms, perform a Grants.gov (<https://www.grants.gov/>) basic search using the Funding Opportunity Number **W81XWH-19-S-CRRP**. Contact information for the CDMRP Help Desk and the Grants.gov Contact Center can be found in [Section II.G, Federal Awarding Agency Contacts](#).

### **II.D.2. Content and Form of the Proposal/Application Submission**

Submission is a two-step process requiring both *pre-application (LOI)* and *full proposal/application* as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods.

**Pre-Application (LOI) Submission:** All pre-applications (LOIs) must be submitted through eBRAP (<https://eBRAP.org/>).

**Full Proposal/Application Submission:** Full proposals/applications must be submitted through Grants.gov (<https://www.grants.gov/>).

Full proposals/applications must be submitted through Grants.gov Workspace. Proposal/applications submitted by extramural organizations (e.g., research foundations) on behalf of intramural DoD or other Federal organizations or investigators will be considered extramural submissions. See definitions in [Section II.C.1, Eligible Applicants](#).

eBRAP allows an organization's representatives and PIs to view and modify the full proposal/application submissions associated with them. eBRAP will validate full proposal/application files against the specific BAA requirements, and discrepancies will be noted in an email to the PI and in the "Full Application Files" tab in eBRAP. It is the applicant's responsibility to review all proposal/application components for accuracy as well as ensure proper ordering as specified in this BAA.

***The proposal/application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application (LOI) and full proposal/application submission process.*** Inconsistencies may delay proposal/application processing and limit or negate the ability to view, modify, and verify the proposal/application in eBRAP. If any changes need to be made, the applicant should contact the CDMRP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507 prior to the proposal/application submission deadline.

## **II.D.2.a. Step 1: Pre-Application (LOI) Submission Content**

*During the pre-application (LOI) process, eBRAP assigns each submission a unique log number. This unique eBRAP log number is required during the full proposal/application submission process.*

All pre-application (LOI) components must be submitted by the PI through eBRAP (<https://eBRAP.org/>).

The applicant organization and associated PI identified in the pre-application (LOI) should be the same as those intended for the subsequent proposal/application submission. If any changes are necessary after submission of the pre-application (LOI), the PI must contact the CDMRP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507.

PIs with an ORCID identifier should enter that information in the appropriate field in the “My Profile” tab in the “Account Information” section of eBRAP.

The pre-application (LOI) consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Submission Instructions, Section II.B, for additional information on pre-application (LOI) submission):

- **Tab 1 – Application Information**

Submission of proposal/application information includes assignment of primary and secondary research classification codes, which may be found at <https://ebrap.org/eBRAP/public/Program.htm>. Note that the codes have recently been revised. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

- **Tab 2 – Application Contacts**

Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 Research & Related Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application (LOI) to be submitted.

Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 Research & Related Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application (LOI) to be submitted.

It is recommended that applicants identify an Alternate Submitter in the event that assistance with pre-application (LOI) submission is needed.

- **Tab 3 – Collaborators and Key Personnel**

Enter the name, organization, and role of all collaborators and key personnel associated with the proposal/application.

[FY19 CRRP Programmatic Panel members](#) should not be involved in any pre-application (LOI) or proposal/application. For questions related to panel members and pre-applications (LOIs) or proposals/applications, refer to [Section II.H.2.c, Withdrawal](#), or contact the CDMRP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507.

- **Tab 4 – Conflicts of Interest**

List all individuals other than collaborators and key personnel who may have a COI in the review of the proposal/application (including those with whom the PI has a personal or professional relationship).

- **Tab 5 – Pre-Application Files**

**Letter of Intent (one-page limit):** Provide a brief description of the research to be conducted. Include the [FY19 CRRP RDTRA Focus Area\(s\)](#) under which the proposal/application will be submitted. LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review sessions.

- **Tab 6 – Submit Pre-Application**

This tab must be completed for the pre-application (LOI) to be accepted and processed.

### **II.D.2.b. Step 2: Full Proposal/Application Submission Content**

*The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.*

Each proposal/application submission must include the completed full proposal/application package for this BAA. The full proposal/application package is submitted by the Authorized Organizational Representative through Grants.gov (<https://www.grants.gov/>). See Table 1 below for more specific guidelines.

#### **II.D.2.b.i. Full Proposal/Application Guidelines**

Extramural organizations must submit full proposals/applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the proposal/application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in Workspace. A compatible version of Adobe Reader **must** be used to view, complete, and submit a proposal/application package consisting of PDF forms. If more than one person is entering text into a proposal/application package, the *same version* of Adobe Reader software should be used by each person. Check the



version number of the Adobe software on each user’s computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Submission Instructions, Section III, and the “Apply For Grants” page of Grants.gov (<https://www.grants.gov/web/grants/applicants/apply-for-grants.html>) for further information about the Grants.gov Workspace submission process. Submissions of extramural proposal/ applications through eBRAP may be withdrawn.

**Table 1. Full Proposal/Application Submission Guidelines**

<b>Proposal/Application Package Location</b>
Download proposal/application package components for W81XWH-19-S-CRRP from Grants.gov ( <a href="https://www.grants.gov">https://www.grants.gov</a> ) and create a Grants.gov Workspace. Workspace allows online completion of the proposal/application components and routing of the proposal/application package through the applicant organization for review prior to submission.
<b>Full Proposal/Application Package Components</b>
<b>SF424 Research &amp; Related Application for Federal Assistance Form:</b> Refer to the General Submission Instructions, Section III.A.1, for detailed information.
Descriptions of each required file can be found under Full Proposal/Application Submission Components: <ul style="list-style-type: none"> <li>• <a href="#">Attachments</a></li> <li>• <a href="#">Research &amp; Related Personal Data</a></li> <li>• <a href="#">Research &amp; Related Senior/Key Person Profile (Expanded)</a></li> <li>• <a href="#">Research &amp; Related Budget</a></li> <li>• <a href="#">Project/Performance Site Location(s) Form</a></li> <li>• <a href="#">Research &amp; Related Subaward Budget Attachment(s) Form</a> (if applicable)</li> </ul>
<b>Proposal/Application Package Submission</b>
<p><b>Create a Grants.gov Workspace.</b> Add participants (investigators and Business Officials) to Workspace, complete all required forms, and check for errors before submission.</p> <p><b>Submit a Grants.gov Workspace Package.</b> A proposal/application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the proposal/application package <b>at least 24-48 hours prior to the close date</b> to allow time to correct any potential technical issues that may disrupt the proposal/application submission.</p> <p><b>Note:</b> If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget needs to be modified, an updated Grants.gov proposal/application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID <i>prior to</i> the proposal/application submission deadline.</p>

### Proposal/Application Verification Period

The full proposal/application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the proposal/application verification period. During the proposal/application verification period, the full proposal/application package may be modified *with the exception of the Project Narrative and Research & Related Budget Form*.

### Further Information

#### **Tracking a Grants.gov Workspace Package.**

After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission.

Refer to the General Submission Instructions, Section III, for further information regarding Grants.gov requirements.

Proposal/application viewing, modification, and verification in eBRAP are strongly recommended, but not required. *The Project Narrative and Research & Related Budget Form cannot be changed after the proposal/application submission deadline.* Prior to the full proposal/application deadline, a corrected or modified full proposal/application package may be submitted. Other proposal/application components may be changed until the end of the proposal/application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the proposal/application verification period. If these components are missing, upload them to eBRAP before the end of the proposal/application verification period. After the end of the proposal/application verification period, the full proposal/application cannot be modified.

The full proposal/application package must be submitted using the unique eBRAP log number to avoid delays in proposal/application processing.

#### **II.D.2.b.ii. Full Proposal/Application Submission Components**

- **SF424 Research & Related Application for Federal Assistance Form:** Refer to the General Submission Instructions, Section III.A.1, for detailed information.
- **Attachments:**

*Each attachment to the full proposal/application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Submission Instructions, Appendix 4.*

For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB, and the file size for the entire full proposal/application package may not exceed 200 MB.

- **Attachment 1: Project Narrative (10-page limit): Upload as “ProjectNarrative.pdf”.** The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the proposal/application.

Describe the proposed project in detail using the outline below. Throughout the Project Narrative, describe how the proposed research is a rapid advancement or innovative “leap ahead” and has the potential for broadly applicable, cross-cutting advances benefiting military health and medicine as well as the general public.

- **Background:** Describe the problem, question, or knowledge gap related to at least one of the [FY19 CRRP RDTRA Focus Areas](#) to be addressed by the proposed project. Present the ideas and reasoning on which the proposed work is based. Cite relevant literature. Describe previous experience most pertinent to the project. Include relevant preliminary data that support proof-of-concept of the product or a prototype/preliminary version of the product; these data may be unpublished or from the published literature. Describe any existing resources which the proposed project will leverage. If the project is part of a larger study, articulate the information that establishes a framework for this study. The proposal/application must demonstrate logical reasoning and provide a sound scientific rationale for the proposed project.
- **Hypothesis or Objective:** State the hypothesis to be tested and/or the objective to be reached.
- **Specific Aims:** Concisely explain the project’s specific aims. These aims should agree with the primary aims and associated tasks described in the SOW. If the proposed work is part of a larger study, present only aims that this DoD award would fund.
- **Research Strategy:** Describe the experimental design, methods, and analyses including appropriate controls in sufficient detail for evaluation. Provide a well-developed, well-integrated research strategy that supports the translational feasibility and promise of the approach.
  - Define the specific study outcomes/endpoints and how they will be measured. Address potential problem areas and present alternative methods and approaches.
  - If animal studies are proposed, briefly describe the key elements of the study/studies as they relate to the overall project. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and how it is optimal for addressing the study aims and facilitates rapid development and translation of solutions for the Warfighter. Describe how animal research will be conducted in accordance with the ARRIVE guidelines ([https://www.elsevier.com/\\_data/promis\\_misc/622936arrive\\_guidelines.pdf](https://www.elsevier.com/_data/promis_misc/622936arrive_guidelines.pdf)).

Further details of research involving animals will be required in [Attachment 7: Animal Research Plan](#), as applicable.

- If human subjects or human biological samples will be used, briefly describe the study population and include a detailed plan for the recruitment of human subjects or the acquisition of samples. Further details of research involving human subjects or human biological substances will be required in [Attachment 6: Human Subject Recruitment and Safety Procedures](#), as applicable. *Clinical trials are not allowed under this funding opportunity.*
  - Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, and identification of primary endpoints and secondary endpoints.
  - Describe the data collection instruments (e.g., surveys, questionnaires, assays) that will be used, and to what degree they are appropriate to support the statistical significance of the proposed study.
  - Clearly describe the statistical plan and the rationale for the statistical methodology. Provide a sample size estimate and the method by which it was derived, including power analysis calculation, if applicable.
  - Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, or international regulatory agency, if applicable.
  - Describe how the background and expertise of the PI and other key personnel demonstrate their understanding of working in military populations or relevant trauma environments. Describe whether the composition of the research or study team is appropriate and complementary.
- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.** Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

*There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the proposal/application.*

References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.

Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

Letters of Organizational Support: Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in this BAA, such as those from members of Congress, do not impact proposal/application review or funding decisions.

Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on a proposal/application submitted through an extramural organization, the proposal/application must include a letter from the collaborator's Commander or Commanding Officer at the intramural organization that authorizes the collaborator's involvement.

Intellectual Property (if applicable):

- Background and Proprietary Information: All software and data first produced under the award are subject to a Federal purpose license. A term of the award requires the recipient to grant the Government all necessary and appropriate licenses, which could include licenses to background and proprietary information that have been developed at private expense. Refer to the General Submission Instructions, Appendix 2, Sections D and E, for more information about disclosure of proprietary information.

Therefore, it is important to disclose/list any intellectual property (software, data, patents, etc.) that will be used in performance of the project or provide a statement that none will be used. If applicable, all proprietary information to be provided to the Government should be stated and identified; the applicant should indicate whether a waiver of the Federal purpose license will be required.

- Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. For proposals/applications involving FITBIR eligible TBI research:

- Identify and describe the planned CDEs, alignment to FITBIR data elements and forms, and timelines for integrating data to the FITBIR Informatics System.
- For UDEs, provide a justification why existing CDEs are not applicable or appropriate.

Refer to the General Submission Instructions, Appendix 2, Section L, for more information about the CDMRP expectations for making data and research resources publicly available.

Use of DoD Resources (if applicable): Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active duty military populations and/or DoD resources or databases.

Use of VA Resources (if applicable): Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the ACOS/R&D or Clinical Service Chief confirming access to VA patients, resources, and/or VA research space. For VA PIs, if the VA NPC is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.** The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. *Do not include proprietary or confidential information.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

The structured technical abstract should be clear and concise and, at a minimum, provide the following information:

- **Background:** Describe the idea and rationale behind the proposed work.
- **Objective/Hypothesis:** State the objective to be reached/hypothesis to be tested. Provide evidence or rationale that supports the hypothesis(es)/objective(s).
- **Specific Aims:** State concisely the specific aims of the study.
- **Study Design:** Briefly describe the study design.
- **Impact and Translation:** Describe the innovative qualities of the proposed work. State the [FY19 CRRP RDTRA Focus Area\(s\)](#) that the research addresses. Indicate how the proposed work will lead to the rapid development and translation of applicable advances for improving medical readiness, mitigating

fatalities, optimally treating life-threatening injuries, and promoting positive long-term outcomes for the military health and medicine, as well as the general public.

- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. *Do not include proprietary or confidential information.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.
  - Describe the objectives and theoretical reasoning behind the proposed work in a manner readily understood by readers without a background in science or medicine. *Do not duplicate the technical abstract.* State the [FY19 CRRP RDTRA Focus Area\(s\)](#) that the research addresses and describe how it is addressed.
  - Describe the problem or question to be addressed and the ultimate applicability and impact of the research.
    - How does the research increase medical readiness, mitigate fatalities, optimally treat life-threatening injuries, and/or promote positive long-term outcomes?
    - Will the research improve delivery of medical damage control capability, assets, and lifesaving interventions?
    - What are the potential clinical applications, benefits, and risks?
  - Describe how the proposed project will benefit Service members, Veterans, military beneficiaries, and/or the American public.
    - How will the research increase survivability and readiness of the Warfighter in diverse operational settings?
- **Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.** The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>). For the RDTRA mechanism, use the SOW format example titled “SOW Generic Format.” The SOW must be in PDF format prior to attaching.

The SOW should include a list of major tasks that support the proposed specific aims, followed by a series of subtasks outlined related to the major tasks and milestones within the period of performance. The SOW should describe only the work for which funding is being requested by this proposal/application and, as applicable, should also:

- Include the name(s) of the key personnel and contact information for each study site/subaward site.

- Indicate the number (and type, if applicable) of research subjects (animal or human) and/or human anatomical samples projected or required for each task and at each site. Refer to the General Submission Instructions, Appendix 1, for additional information regarding regulatory requirements.
- For studies with prospective accrual of human subjects, indicate quarterly enrollment targets.
- If applicable, indicate timelines required for regulatory approvals relevant to human subjects research (e.g., IND and IDE applications) by the FDA or other Government agency.
- **Attachment 6: Human Subject Recruitment and Safety Procedures (no page limit), if applicable; required for all studies recruiting human subjects: Upload as “HumSubProc.pdf”.** The Human Subject Recruitment and Safety Procedures attachment should include the components listed below.

*Applicants and collaborating organizations may not use, employ, or subcontract for the use of any human participants, including the use of human anatomical substances, human data, and/or human cadavers until applicable regulatory documents are reviewed and approved by the USAMRDC ORP to ensure that DoD regulations have been met.*

- **Study Population:** Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site(s) (population from whom the sample will be recruited/drawn). Provide a table of anticipated enrollment counts at each study site. Demonstrate that the research team has access to the proposed study population at each site, and describe the efforts that will be made to achieve accrual goals. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical studies (if applicable). Address any potential barriers to accrual and plans for addressing unanticipated delays, including a mitigation plan for slow or low enrollment. Identify ongoing clinical studies that may compete for the same patient population and how they may impact enrollment progress. Provide justification related to the scientific goals of the proposed study for limiting inclusion of any group by age, race, ethnicity, or sex/gender. *For clinical research proposing to include military personnel, refer to the General Submission Instructions, Appendix 1, for more information.*

**Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed clinical study. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.

**Inclusion of Women and Minorities in Study.** Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and Congressional legislation, special attention is given to inclusion of women and/or



minorities in studies funded or supported by the USAMRDC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Include an appropriate justification if women and/or minorities will be excluded from the clinical study.

**Description of the Recruitment Process:** Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, healthcare provider identification).

- Describe the recruitment process in detail. Address who will identify potential human subjects, who will recruit them, and what methods will be used to recruit them.
- If human subjects will be compensated for participation in the study, include a detailed description of and justification for the compensation plan.
- Describe the recruitment and advertisement materials. The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study.

**Description of the Informed Consent Process:** Specifically describe the plan for obtaining informed consent from human subjects.

- *For the proposed study, provide a draft, in English, of the Informed Consent Form. FITBIR eligible proposals/applications should include FITBIR consent language (see [Appendix III](#)) for sample consent language.*
- Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects' questions will be addressed during the consent process and throughout the study.
- Include information regarding the timing and location of the consent process.
- Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.
- Address how privacy and time for decision making will be provided and whether or not the potential human subject will be allowed to discuss the study with anyone before making a decision.
- Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.
- Describe the plan for the consent of the individual's Legally Authorized Representative (LAR) to be obtained prior to the human subject's participation in

the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. **Note:** In compliance with 10 USC 980 (<https://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf>), the proposal/application must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed clinical study. If applicable, refer to the General Submission Instructions, Appendix 1, for more information.

- **Assent.** If minors or other populations that cannot provide informed consent are included in the proposed clinical study, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.

**Screening Procedures:** List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry.

**Note:** Some screening procedures may require a separate consent or a two-stage consent process.

**Risks/Benefits Assessment:**

- **Foreseeable risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is exposed to as a result of participation in the clinical study. Consider psychological, legal, social, and economic risks as well as physical risks. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.
- **Risk management and emergency response:**
  - ❖ Describe how safety surveillance and reporting to the IRB and FDA (if applicable) will be managed and conducted.
  - ❖ Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel or to manage unpreventable risks. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
  - ❖ Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, including who will be responsible for the cost of such care.
  - ❖ Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, and pregnancy prevention).

- ❖ Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.
- ❖ If the IRB determines that a study presents greater than minimal risk to human subjects, the DoD requires an independent research monitor with expertise consistent with the nature of risk(s) identified within the research protocol. If applicable, refer to the General Submission Instructions, Appendix 1, Section B (Research Monitor Requirement), for more information on study reporting authorities and responsibilities of the research monitor.
- **Potential benefits:** Describe known and potential benefits of the study to the human subjects who will participate in the study. Articulate the importance of the knowledge to be gained as a result of the proposed research. Discuss why the potential risks to human subjects are reasonable in relation to the anticipated benefits to the human subjects and others that may be expected to result.
- **Attachment 7: Animal Research Plan (if applicable; required for all studies utilizing animals; five-page limit): Upload as “AnimRschPln.pdf”.**

When the proposed study involves animals, the applicant is required to submit a summary describing the animal research that will be conducted. Applicants should not submit a verbatim replica of the protocol(s) to be submitted to the IACUC as the Animal Research Plan. The Animal Research Plan should address the following points for each proposed animal study:

- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology.
- For studies using non-gyrencephalic (lissencephalic) animal models of TBI, include justification for their use.
- Summarize the procedures to be conducted. Describe how the study will be controlled.
- Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
- Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
- Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).

- Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.
- **Attachment 8: Transition Plan and Regulatory Strategy (three-page limit): Upload as “Transition.pdf”.**

Describe the methods and strategies proposed to enable the product or knowledge outcomes to move to the next phase of development (e.g., clinical trials, partnership with DoD advanced developers, commercialization, and/or delivery to the civilian or military market) after successful completion of the award. Estimate a target technology readiness level (TRL) or knowledge readiness level (KRL) for the proposed product or knowledge outcome ([Appendix IV](#)). Outline the regulatory strategy. Applicants are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. PIs are encouraged to explore developing relationships with industry, DoD advanced developers, and/or other funding agencies to facilitate moving the product into the next phase of development. The transition plan should include the components listed below.

The planned indication for the product label, if appropriate, and an outline of the development plan required to support that indication (e.g., Target Product Profile). Describe in detail the FDA regulatory strategy, including the number and types of studies proposed to reach approval, licensure, or clearance, the types of FDA meetings to be held, the submission filing strategy, and considerations for compliance with Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), and Good Clinical Practice (GCP) guidelines, if appropriate.

Details of the funding strategy to transition the product(s) to the next level of development and/or commercialization (e.g., specific potential industry partners, specific funding opportunities to be applied for). Include a description of collaborations and other resources that will be used to provide continuity of development.

For Knowledge Products, a description of collaborations and other resources that will be used to provide continuity of development, including proposed development or modification of clinical practice guidelines and recommendations, provider training materials, patient brochures, and other clinical support tools, scientific journal publications, models, simulations, and applications.

A brief schedule and milestones for transitioning the product(s) to the next phase of development (e.g., next-phase clinical trials, transition to industry, delivery to the civilian and/or military market, incorporation into clinical practice, and/or approval by the FDA).

Ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the Government’s ability to access such products or technologies in the future.

A risk analysis for cost, schedule, manufacturability, and sustainability.

- **Attachment 9: Impact Statement (two-page limit): Upload as “Impact.pdf”.**

Explain in detail how the research represents an accelerated approach for existing research and technologies, aligned to the [FY19 CRRP RDTRA Focus Area\(s\)](#). Describe how the research is cross-cutting with the potential to benefit multiple DoD medical research program areas.

Describe how the proposed research, if successful, will significantly improve the readiness of the Force in combat and frontline trauma environments.

Describe how the anticipated outcomes will be translated into clinical applications and advancements in military health and medicine.

Describe how the proposed research project, if successful, will advance operational performance, medical readiness, or quality of life of Service members or Veterans. Also describe how the proposed research will benefit their families, caregivers, and the American public, as applicable. Include the timeline to realize the anticipated outcomes of the research. Expand upon the dual (military and public) purpose for the research, as appropriate.

- **Attachment 10: Representations: Upload as “RequiredReps.pdf”.** All applicants must complete and submit the Required Representations template available on eBRAP (<https://ebrap.org/eBRAP/public/Program.htm>). For more information, see the General Submission Instructions, Appendix 5, Section B, Representations.
- **Attachment 11: DoD Military Budget Form(s), if applicable: Upload as “MFBudget.pdf”.** If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DoD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete the DoD Military Budget Form, available for download on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Submission Instructions, Section III.A.8, for detailed information.

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC A§1681 et seq.), the DoD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in proposals/applications in science, technology, engineering, and/or mathematics (STEM) disciplines. To enable this assessment, each proposal/application must include the following forms completed as indicated.

**Research & Related Personal Data:** Refer to the General Submission Instructions, Section III.A.3.

**Research & Related Senior/Key Person Profile (Expanded):** Refer to the General Submission Instructions, Section III.A.4.

- **PI Biographical Sketch (five-page limit):** Upload as “Biosketch\_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP. The National Institutes of Health (NIH) Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.
- **PI Previous/Current/Pending Support (no page limit):** Upload as “Support\_LastName.pdf”.
- **Key Personnel Biographical Sketches (five-page limit each):** Upload as “Biosketch\_LastName.pdf”.
- **Key Personnel Previous/Current/Pending Support (no page limit):** Upload as “Support\_LastName.pdf”.

**Research & Related Budget:** Refer to the General Submission Instructions, Section III.A.5.

**Budget Justification (no page limit):** Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

**Project/Performance Site Location(s) Form:** Refer to the General Submission Instructions, Section III.A.6.

**Research & Related Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Submission Instructions, Section III.A.7, for detailed information.

- **Extramural Subaward:** Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Submission Instructions, Section III.A, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the proposal/application verification period. If these components are missing, upload them to eBRAP before the end of the proposal/application verification period.

**Note:** Proposals/applications from **Federal agencies** must include a **Federal Financial Plan** in their budget justifications. Proposals/applications from organizations that include **collaborations with DoD Military Facilities** must comply with special requirements. Refer to the General Submission Instructions, Section III.A.5, Research & Related Budget, for detailed information.

### **II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM)**

Applicant organizations and all subrecipient organizations must have a DUNS number to submit proposals/applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit proposals/applications through the Grants.gov portal. Verify the status of the applicant organization’s Entity registration in SAM well in advance of the proposal/application submission deadline. Allow several weeks to complete the entire SAM registration process.

Applicants must maintain an “Active” SAM status to be qualified to receive Federal awards. If an applicant is not fully compliant with the requirements at the time the Federal awarding agency is ready to make a Federal award, the Federal awarding agency may determine that the applicant is not qualified to receive a Federal award and use that determination as a basis for making a Federal award to another applicant.

**Refer to the General Submission Instructions, Section III, for further information regarding Grants.gov requirements.**

### **II.D.4. Submission Dates and Times**

All submission dates and times are indicated in [Section I, Overview of the Funding Opportunity](#). Pre-application (LOI) and proposal/application submissions are required. The pre-application (LOI) and proposal/application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

#### **Applicant Verification of Full Proposal/Application Submission in eBRAP**

Following retrieval and processing of the full proposal/application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full proposal/application submission. eBRAP will validate retrieved files against the specific BAA requirements, and discrepancies will be noted in both the email and in the “Full Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all proposal/application components and ensure proper ordering as specified in the BAA. ***If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full proposal/application package must be submitted prior to the proposal/application submission deadline.*** The Project Narrative and Budget Form cannot be changed after the application submission deadline.

The full proposal/application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the proposal/application verification period. During the proposal/application verification period, the full proposal/application package, ***with the exception of the Project Narrative and Budget Form***, may be modified.

Verify that subaward budget(s) with budget justification are present in eBRAP during the proposal/application verification period. If these components are missing, upload them to eBRAP before the end of the proposal/application verification period.

### **II.D.5. Intergovernmental Review**

This BAA is not subject to Executive Order (EO) 12372, “Intergovernmental Review of Federal Programs.” The EO provides for state and local government coordination and review of proposed Federal financial assistance and direct Federal development. The EO allows each state to designate an entity to perform this function. This coordination and review is not required under this BAA.

### **II.D.6. Funding Restrictions**

The maximum period of performance is **2 years**.

The anticipated direct costs budgeted for the entire period of performance will not exceed **\$1,500,000**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding **\$1,500,000** direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **2 years**.

For this award mechanism, direct costs must be requested for:

- Travel costs for the PI to present project information or disseminate project results at a DoD-sponsored meeting (e.g., progress review meeting or Military Health System Research Symposium) in year 2 of the award. For planning purposes, it should be assumed that the meeting will be held in the Central Florida Area. These travel costs are in addition to those allowed for annual scientific/technical meetings.

May be requested for (not all-inclusive):

- Salary
- Research supplies
- Research-related subject costs
- Clinical research costs
- Support for multidisciplinary collaborations, including travel
- Travel costs for one investigator to travel to one scientific/technical meeting per year in addition to the required meeting described above. The intent of travel costs to scientific/technical meetings is to present project information or disseminate project results from the CRRP RDTRA.



Must not be requested for:

- Clinical trial costs
- Equipment

Awards made to extramural organizations will consist of contracts or assistance agreements (grants and cooperative agreements). For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DoD or other Federal agency is not allowed except under very limited circumstances. Funding to intramural DoD and other Federal agencies will be managed through a direct funds transfer. Intramural applicants are responsible for coordinating through their agency's procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Submission Instructions, Section III.A.5, for budget regulations and instructions for the Research & Related Budget. *For Federal agencies or organizations collaborating with Federal agencies, budget restrictions apply as are noted in the General Submission Instructions, Section III.A.5.*

Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. The time is considered when establishing the award's period of performance. It is anticipated that awards made from this FY19 funding opportunity will be funded with FY19 funds, which will expire for use on September 30, 2025.

#### **II.D.7. Other Submission Requirements**

Refer to the General Submission Instructions, Appendix 4, for detailed formatting guidelines.

### **II.E. Proposal/Application Review Information**

#### **II.E.1. Criteria**

##### **II.E.1.a. Peer Review**

To determine technical merit, all proposals/applications will be evaluated according to the following **scored criteria**, which are listed in decreasing order of importance:

- **Impact**
  - How well the proposed work represents an accelerated and relevant approach aligned to the [FY19 CRRP RDTRA Focus Areas](#).
  - How well the project outcomes will translate into clinical applications and advancements in military health and medicine.

- To what extent, the proposed research, if successful, will significantly improve the readiness of the Force in combat and frontline trauma environments.
- To what degree the anticipated outcomes of the proposed project will lead to improved operational performance, medical readiness, or quality of life for the Warfighter.
- **Research Strategy and Feasibility**
  - How well the scientific rationale supports the project and its translational feasibility as demonstrated by a critical review and analysis of published literature, logical reasoning, and preliminary data, if applicable.
  - How well the hypothesis, objectives, specific aims, experimental design, methods, and analyses are developed.
  - How well the proposal/application acknowledges potential problems and addresses alternative approaches.
  - To what extent proposed animal models, if applicable, are appropriate for the scientific aims and research approach and facilitate rapid development and solutions for the Warfighter.
  - Whether the applicant demonstrates access to the relevant study population or resources.
  - If applicable, the degree to which the intellectual and material property plan is appropriate.
  - Whether the research can be completed within the proposed period of performance.
  - For FITBIR eligible proposals/applications:
    - How well the study utilizes TBI CDEs and describes processes and timelines for integrating data to the FITBIR Informatics System.
    - If UDEs are utilized, how well the proposal/application justifies the rationale for UDE collection.
- **Transition Plan and Regulatory Strategy**
  - Whether the identified next level of development and/or plan for commercialization, if applicable, is realistic.
  - Whether the schedule and milestones for bringing the anticipated product(s) to the next level of development (clinical trials, transition to industry, delivery to the military or civilian market, incorporation into clinical practice, or approval by the FDA) are achievable. Whether the potential risk analysis for cost, schedule, manufacturability, and sustainability is realistic and reasonable.

- Whether the funding strategy described to bring the product(s) to the next level of development (e.g., specific potential industry partners, specific funding opportunities to be applied for) is reasonable and realistic.
- Whether the regulatory strategy and the development plan to support the proposed product label, if applicable, are appropriate and well described.
- If applicable, whether the proposed collaborations and other resources for providing continuity of development of knowledge products, including proposed development or modification of clinical practice guidelines and recommendations, provider training materials, patient brochures, and other clinical support tools, scientific journal publications, models, simulations, and applications are established and/or achievable.
- **Ethical Considerations (for studies recruiting human subjects)**
  - How well the evidence shows that procedures are consistent with sound research design, and when appropriate, that these procedures are already in use for diagnostic or treatment purposes.
  - Whether the level of risk is minimized and communicated through informed consent.
  - How well safeguards are described and in place for vulnerable populations.
  - To what degree privacy issues are appropriately considered.
- **Statistical and Data Analysis Plan**
  - How well the proposed research is designed to achieve reproducible and rigorous results, including controls, sample size estimation, randomization, statistical analysis, and data handling.
  - How the statistical plan, including sample size projections and power analysis, is adequate to achieve the study objectives and is appropriate to type and phase of study.
  - If applicable, description of the population(s) of interest, demonstration of access to these populations, and identification of sampling methods to gain a representative sample from the population(s) of interest.
  - To what degree the data collection instruments (e.g., surveys, questionnaires, assays), if applicable, are appropriate to support statistical significance of the proposed study.
- **PI and Key Personnel Qualifications**
  - Whether the background and expertise of the PI and other key personnel demonstrate their ability to perform the proposed work.
  - Whether the levels of effort by the PI and other key personnel are appropriate to ensure the successful conduct of the project.

- Whether the PI's record of accomplishment demonstrates his/her ability to accomplish the proposed work.

- **Environment**

- Whether the scientific environment is appropriate for the proposed research.
- How the quality and extent of organizational support are appropriate for the proposed research.
- How the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).

In addition, the following **unscored** criteria will also contribute to the overall evaluation of the proposal/application:

- **Budget**

- Whether the **direct** maximum costs are equal to or less than the allowable direct maximum costs as published in this BAA.
- Whether the budget is appropriate for the proposed research.

- **Proposal/Application Presentation**

- To what extent the writing, clarity, and presentation of the proposal/application components influence the review.

### **II.E.1.b. Programmatic Review**

To make funding recommendations and select the proposal(s)/application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Relevance to the mission of the DHP and FY19 CRRP, as evidenced by the following:
  - Adherence to the intent of the award mechanism
  - Program portfolio composition
  - Relevance to military health
  - Relative impact and translatability

## **II.E.2. Proposal/Application Review and Selection Process**

All proposals/applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of proposal/applications against established criteria to determine technical merit, where each proposal/application is assessed for its own merit, independent of other proposals/applications. The second tier is **programmatic review**, a comparison-based process in which proposals/applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC, on behalf of the DHA and the OASD(HA). *The highest-scoring proposals/applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in [Section II.E.1.b, Programmatic Review](#).* Additional information about the two-tier process used by the CDMRP can be found at <https://cdmrp.army.mil/about/2tierRevProcess>. A PI Information Paper describing the funding recommendations and review process for the CRRP RDTRA will be provided to the PI and posted on the CDMRP website.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that proposal/application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization's proposal/application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from Federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

## **II.E.3. Integrity and Performance Information**

Prior to making an assistance agreement award where the Federal share is expected to exceed the simplified acquisition threshold (currently \$250,000) over the period of performance, the Federal awarding agency is required to review and consider any information about the applicant that is available in the FAPIIS.

An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a Federal awarding agency previously entered and is currently available in FAPIIS.

The Federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics, and record of performance under Federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415 and/or FAR 9.104-1.

#### **II.E.4. Anticipated Announcement and Federal Award Dates**

All proposal/application review dates and times are indicated in [Section I, Overview of the Funding Opportunity](#).

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the proposal/application.

A recommended for funding notification is NOT an authorization to begin performance or a guarantee of an award. Awards are contingent upon availability of funding, adequacy of supporting documentation submitted, fulfillment of all requirements, and completion of successful negotiations. Authorization to begin performance will be received via an award document (contract, grant, or cooperative agreement, as applicable) signed by the USAMRAA Contracting or Grants Officer. Awards may be issued at any time throughout the year.

#### **II.F. Award Administration Information**

##### **II.F.1. Award Notices**

Awards supported with FY19 funds are anticipated to be made no later than September 30, 2020. Refer to the General Submission Instructions, Appendix 2, for additional award administration information.

After email notification of proposal/application review results through eBRAP, and if selected for funding, a representative from USAMRAA will contact the Business Official authorized to negotiate on behalf of the PI's organization.

*Only an appointed USAMRAA Contracting or Grants Officer may obligate the Government to the expenditure of funds.* No commitment on the part of the Government should be inferred from discussions with any other individual. **The award document signed by the USAMRAA Contracting or Grants Officer is the official authorizing document.**

**Federal Government Organizations:** Funding made to Federal Government organizations (to include intramural DoD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals.

##### **II.F.1.a. PI Changes and Award Transfers**

Refer to the General Submission Instructions, Appendix 2, Section B, for general information on organization or PI changes.

##### **II.F.2. Administrative and National Policy Requirements**

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this BAA.

Applicable requirements in the FAR, found in 48 CFR, Chapter 1, DFARS, found in 48 CFR Chapter 2, and AFARS, found in 48 CFR Chapter 51, apply to contracts resulting from this BAA.

Refer to the General Submission Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Submission Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest [DoD R&D General Terms and Conditions](#), the [USAMRAA General Research Terms and Conditions with Institutions of Higher Education, Hospitals, and Non-Profit Organizations](#): Addendum to the DoD R&D General Terms and Conditions and the [USAMRAA General Research Terms and Conditions with For-Profit Organizations](#) for further information.

### **II.F.3. Reporting Requirements**

Refer to the General Submission Instructions, Appendix 2, Section A, for general information on reporting requirements. *If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.*

Quarterly technical progress reports and quad charts, as well as annual and final technical progress reports will be required.

In addition to written progress reports, in-person presentations may be requested.

Awards resulting from this BAA will incorporate additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have Federal contract, grant, and cooperative agreement awards with a cumulative total value greater than \$10,000,000 are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a Federal award. Recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Submission Instructions, Appendix 5).

### **II.G. Agency Contacts**

#### **II.G.1. CDMRP Help Desk**

Questions related to BAA content or submission requirements as well as questions related to the pre-application (LOI) submission through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507

Email: [help@eBRAP.org](mailto:help@eBRAP.org)

## **II.G.2. Grants.gov Contact Center**

Questions related to full proposal/application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726; International 1-606-545-5035

Email: [support@grants.gov](mailto:support@grants.gov)

Sign up on Grants.gov for “send me change notification emails” by following the link on the “Synopsis” page for the BAA or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the proposal/application package may not be accepted by Grants.gov.

## **II.H. Other Information**

### **II.H.1. Administrative Actions**

After receipt of proposals/applications, the following administrative actions may occur:

#### **II.H.1.a. Rejection**

The following will result in administrative rejection of the proposal/application:

- Pre-application (LOI) was not submitted.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.

*For proposals/applications involving animal research:*

- [Attachment 7: Animal Research Plan](#) is missing.

*For proposals/applications recruiting human subjects:*

- [Attachment 6: Human Subject Recruitment and Safety Procedures Plan](#) is missing.



### **II.H.1.b. Modification**

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

### **II.H.1.c. Withdrawal**

The following may result in administrative withdrawal of the proposal/application:

- An FY19 CRRP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application (LOI) or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. *A list of the FY19 CRRP Programmatic Panel members can be found at <https://cdmrp.army.mil/crrp/panels/panels19>.*
- The proposal/application fails to conform to this BAA description.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted proposals/applications. For FY19, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (<https://cdmrp.army.mil/about/2tierRevProcess>). Proposals/applications that include names of personnel from either of these companies may be administratively withdrawn.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- Proposals/applications from extramural organizations, including non-DoD Federal agencies, received through eBRAP may be withdrawn.
- Proposals/applications submitted by an intramural DoD organization will be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.
- A clinical trial is proposed.

#### **II.H.1.d. Withhold**

Proposals/applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Contracting or Grants Officer for a determination of the final disposition of the proposal/application.

## II.H.2. Proposal/Application Submission Checklist

Proposal/Application Components	Action	Completed
SF424 Research & Related Application for Federal Assistance	Complete form as instructed	
Attachments	Project Narrative: Upload as Attachment 1 with file name "ProjectNarrative.pdf"	
	Supporting Documentation: Upload as Attachment 2 with file name "Support.pdf"	
	Technical Abstract: Upload as Attachment 3 with file name "TechAbs.pdf"	
	Lay Abstract: Upload as Attachment 4 with file name "LayAbs.pdf"	
	Statement of Work: Upload as Attachment 5 with file name "SOW.pdf"	
	Human Subject Recruitment and Safety Procedures: Upload as Attachment 6 with file name "HumSubProc"	
	Animal Research Plan: Upload as Attachment 7 with file name "AnimRschPln.pdf"	
	Transition Plan and Regulatory Strategy: Upload as Attachment 8 with file name "Transition.pdf"	
	Impact Statement: Upload as Attachment 9 with file name "Impact.pdf"	
	Representations: Upload as Attachment 10 with file name "RequiredReps.pdf"	
	DoD Military Budget Form(s): Upload as Attachment 11 with file name "MFBudget.pdf" if applicable	
Research & Related Personal Data	Complete form as instructed	

<b>Proposal/Application Components</b>	<b>Action</b>	<b>Completed</b>
Research & Related Senior/Key Person Profile (Expanded)	Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field	
	Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field	
	Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field	
	Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field	
Research & Related Budget	Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field	
Project/Performance Site Location(s) Form	Complete form as instructed	
Research & Related Subaward Budget Attachment(s) Form, if applicable	Complete form as instructed	

## APPENDIX I: ACRONYM LIST

ACOS/R&D	Associate Chief of Staff for Research and Development
ACURO	Animal Care and Use Review Office
AFARS	Army Federal Acquisition Regulation Supplement
ARRIVE	Animal Research: Reporting <i>In Vivo</i> Experiments
BAA	Broad Agency Announcement
CDE	Common Data Element
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CICA	Competition in Contracting Act
COI	Conflict of Interest
CRRP	Combat Readiness – Medical Research Program
DFARS	Defense Federal Acquisition Regulation Supplement
DHA	Defense Health Agency
DHHS	U.S. Department of Health and Human Services
DHP	Defense Health Program
DoD	Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DUNS	Data Universal Numbering System
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
EO	Executive Order
ET	Eastern Time
FAD	Funding Authorization Document
FAPIIS	Federal Awardee Performance and Integrity Information System
FAR	Federal Acquisition Regulation
FDA	U.S. Food and Drug Administration
FFRDC	Federally Funded Research and Development Center
FY	Fiscal Year
GCP	Good Clinical Practice
GLP	Good Laboratory Practice
GMP	Good Manufacturing Practice
GUID	Global Unique Identifier
HIPAA	Health Insurance Portability and Accountability Act
HRPO	Human Research Protection Office
HUBZone	Historically Underutilized Business Zone
IACUC	Institutional Animal Care and Use Committee
IDE	Investigational Device Exemption
IND	Investigational New Drug
IRB	Institutional Review Board
KP	Knowledge Product

KRL	Knowledge Readiness Level
LAR	Legally Authorized Representative
LOI	Letter of Intent
M	Million
MDO	Multi-domain operation
MIPR	Military Interdepartmental Purchase Request
MIT	Massachusetts Institute of Technology
NIH	National Institutes of Health
NINDS	National Institute of Neurological Disorders and Stroke
NPC	Non-Profit Corporation
OASD(HA)	Office of the Assistant Secretary of Defense for Health Affairs
ORCID	Open Researcher and Contributor ID, Inc.
ORP	Office of Research Protections
PI	Principal Investigator
PII	Personally Identifiable Information
PTSD	Post-Traumatic Stress Disorder
RCT	Randomized Controlled Trial
RDT&E	Research, Development, Test, and Evaluation
RDTRA	Rapid Development and Translational Research Award
SAM	System for Award Management
SOW	Statement of Work
STEM	Science, Technology, Engineering, and/or Mathematics
TBI	Traumatic Brain Injury
TRA	Technology Readiness Assessment
TRL	Technology Readiness Level
UDE	Unique Data Element
USAMRAA	U.S. Army Medical Research Acquisition Activity
USAMRDC	U.S. Army Medical Research and Development Command
USC	United States Code
VA	Department of Veterans Affairs

## APPENDIX II: DOD AND VA WEBSITES

PIs are encouraged to integrate and/or align their research projects with DoD and/or VA research laboratories and programs. Collaboration with DoD and/or VA investigators is also encouraged. Below is a list of websites that may be useful in identifying additional information about DoD and VA areas of research interest, ongoing research or potential opportunities for collaboration.

Air Force Office of Scientific Research  
<https://afrl.dodlive.mil/about/>

Air Force Research Laboratory  
<https://afrl.dodlive.mil/>

Armed Forces Radiobiology Research  
Institute  
<https://www.usuhs.edu/afri/>

Clinical and Rehabilitative Medicine  
Research Program  
<https://crmrp.amedd.army.mil>

Combat Casualty Care Research Program  
<https://ccc.amedd.army.mil>

Congressionally Directed Medical Research  
Programs  
<https://cdmrp.army.mil>

Defense Advanced Research Projects  
Agency  
<https://www.darpa.mil/>

Defense Health Agency  
<https://health.mil/dha>

Defense Technical Information Center  
<https://www.dtic.mil>

Defense Threat Reduction Agency  
<https://www.dtra.mil/>

Military Health System Research  
Symposium  
<https://mhsrs.amedd.army.mil/SitePages/Home.aspx>

Military Infectious Diseases Research  
Program  
<https://midrp.amedd.army.mil>

Military Operational Medicine Research  
Program  
<https://momrp.amedd.army.mil>

Naval Health Research Center  
<https://www.med.navy.mil/sites/nhrc>

Navy Bureau of Medicine and Surgery  
<https://www.med.navy.mil/>

Naval Medical Research Center  
[www.med.navy.mil/sites/nmrc](http://www.med.navy.mil/sites/nmrc)

Navy and Marine Corps Public Health  
Center  
<https://www.nmcphc.med.navy.mil/>

Office of Naval Research  
<https://www.onr.navy.mil/>

Office of the Under Secretary of Defense for  
Acquisition, Technology and Logistics  
<https://www.acq.osd.mil/>

Telemedicine and Advanced Technology  
Research Center  
<https://www.tatrc.org/s>

Uniformed Services University of the Health  
Sciences  
<https://www.usuhs.edu/research>

U.S. Air Force 59<sup>th</sup> Medical Wing  
<https://www.59mdw.af.mil/>

U.S. Army Aeromedical Research  
Laboratory  
<https://www.usaarl.army.mil/>

U.S. Army Combat Capabilities  
Development Command  
<https://www.army.mil/ccdc>

U.S. Army Institute of Surgical Research  
<https://usaisr.amedd.army.mil/>

U.S. Army Research Institute of  
Environmental Medicine  
<https://www.usariem.army.mil/>

U.S. Army Medical Research Institute of  
Infectious Diseases  
<https://www.usamriid.army.mil/>

U.S. Army Medical Research and  
Development Command  
<https://mrdc.amedd.army.mil>

U.S. Army Research Laboratory  
<https://www.arl.army.mil>

U.S. Army Sharp, Ready and Resilient  
Directorate  
<https://www.army.mil/readyandresilient/>

U.S. Department of Defense Blast Injury  
Research Program  
<https://blastinjuryresearch.amedd.army.mil/>

U.S. Department of Veterans Affairs, Office  
of Research and Development  
<https://www.research.va.gov>

U.S. Naval Research Laboratory  
<https://www.nrl.navy.mil>

Walter Reed Army Institute of Research  
<https://www.wrair.army.mil/>



## **APPENDIX III: SAMPLE FITBIR CONSENT LANGUAGE**

Data from this study may be submitted to the Federal Interagency Traumatic Brain Injury (FITBIR) informatics system. FITBIR is a computer system run by the National Institutes of Health that allows researchers studying traumatic brain injury to collect and share information with each other. With an easier way to share, researchers hope to learn new and important things about traumatic brain injury more quickly than before.

During and after the study, the researchers will send information about you or your child's health and behavior and in some cases, you or your child's genetic information, to FITBIR. However, before they send it to FITBIR, they will remove information such as name, date of birth, and city of birth, and replace that information with a code number. Other researchers nationwide can then file an application to obtain access to your study data for research purposes. Experts who know how to protect health and science information will look at every request carefully to minimize risks to your privacy.

You or your child may not benefit directly from allowing your information to be shared with FITBIR. The information provided to FITBIR might help researchers around the world treat future children and adults with traumatic brain injury so that they have better outcomes. FITBIR will report on its website about the different studies that researchers are conducting using FITBIR data; however, FITBIR will not be able to contact you or your child individually about specific studies.

You may decide now or later that you do not want to share you or your child's information using FITBIR. If so, contact the researchers who conducted this study, and they will tell FITBIR, which can stop sharing the research information. However, FITBIR cannot take back information that was shared before you changed your mind. If you would like more information about FITBIR, this is available on-line at <http://fitbir.nih.gov>

### **Language to be used to describe certificates of confidentiality (three versions):**

#### **1. Language for new studies that will be consenting subjects for the first time or for ongoing studies that will be re-consenting subjects because they are applying for a Certificate of Confidentiality for the study**

To help protect you and/or your child's privacy the investigators of this study [have applied for]/[have obtained] a Certificate of Confidentiality from the National Institutes of Health (NIH), part of the U.S. Department of Health and Human Services (DHHS), an agency of the U.S. Government.

With this Certificate, we, the investigators, cannot be forced (e.g., by court subpoena) to disclose information that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings. Be aware that disclosure of you and/or your child's identity may be found necessary, however, upon request of DHHS for the purpose of audit or evaluation.

You should also understand that a Confidentiality Certificate does not prevent you or a member of your family from **voluntarily** releasing information about your child, yourself, or your involvement in this research. Note, however, that if an insurer or employer learns about you

and/or your child's participation, and obtains your consent to receive research information, then the investigator may not use the Certificate of Confidentiality to withhold this information. This means that you and your family must also actively protect your own privacy.

We are also asking your consent to provide research data and related findings to the Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system. FITBIR is a biomedical informatics system and data repository, created by the Department of Defense and the National Institutes of Health to assist biomedical researchers working to develop a better understanding of traumatic brain injury and/or to develop more effective methods to diagnose, treat and prevent traumatic brain injuries.

Data entered into FITBIR will be kept confidential, with FITBIR being designed for access by qualified researchers only. Data provided to FITBIR as part of you and/or your child's participation in this research study will be de-identified—i.e., you and/or your child's name will be separated from the data. However, since this institution and others submitting data to FITBIR will retain individually identifying information related to the data they provide, NIH has issued a legislatively authorized "Certificate of Confidentiality" that will help FITBIR and participating institutions avoid being forced to disclose information that may identify you as a FITBIR participant in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings.

Finally, you should understand that we, the investigators, are not prevented from taking steps, including reporting to authorities, to prevent serious harm to you, your child, or others. With respect to you and/or your child's participation in FITBIR, we do not plan to make voluntary disclosures except if there were severe threats to the public health or safety.

## **2. Language for studies that already have a Certificate and will be re-consenting subjects about FITBIR**

With your consent, this study will collect and provide research data and related findings to the Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system. FITBIR is a biomedical informatics system and data repository created by the Department of Defense and National Institutes of Health (NIH)—part of the U.S. Department of Health and Human Services (DHHS), an agency of the U.S. Government—to assist biomedical researchers working to develop a better understanding of traumatic brain injury and/or to develop more effective methods to diagnose, treat and prevent traumatic brain injury.

Data entered into FITBIR will be kept confidential, with FITBIR being designed for access by researchers only. Data provided to FITBIR as part of you and/or your child's participation in this research study will be de-identified—i.e., you and/or your child's name will be separated from the data. However, since this institution and others submitting data to FITBIR will retain individually identifying information related to the data they provide, NIH has issued a legislatively authorized "Certificate of Confidentiality" to help FITBIR and participating institutions avoid being forced (e.g., by court subpoena) to disclose information that may identify you as an FITBIR participant in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings. Be aware that disclosure of you and/or your child's identity may be found necessary, however, upon request of DHHS for the purpose of audit or evaluation.

As you know, we have obtained a Certificate of Confidentiality from NIH that enables us to keep the individually identifiable information that you provide as a research subject private. With this Certificate, we, the investigators cannot be forced to disclose research information collected in this study that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings. This protection will continue to protect you and/or your child's privacy even though we are providing de-identified data to FITBIR.

You should also understand that a Confidentiality Certificate does not prevent you or a member of your family from **voluntarily** releasing information about your child, yourself, or your involvement in this research. Note, however, that if an insurer or employer learns about you and/or your child's participation and obtains your consent to receive research information, then the investigator may not use the Certificate of Confidentiality to withhold this information. This means that you and your family must also actively protect your own privacy.

Finally, as we explained when we told you about this privacy protection before, we, the investigators, are not prevented from taking steps, including reporting to authorities, to prevent serious harm to you and/or your child or others based on information they learn during this study. With respect to you and/or your child's participation in FITBIR, we do not plan to make voluntary disclosures except if there were severe threats to the public health or safety.

### **3. Language for studies without a Certificate of their own**

With your consent, this study will collect and provide research data and related findings to the Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system. FITBIR is a biomedical informatics system and data repository created by the Department of Defense and the National Institutes of Health (NIH)—part of the U.S. Department of Health and Human Services (DHHS), an agency of the U.S. Government—to assist biomedical researchers working to develop a better understanding of traumatic brain injury and/or to develop more effective methods to diagnose, treat and prevent traumatic brain injury.


Data entered into FITBIR will be kept confidential, with FITBIR being designed for access by researchers only. Data provided to FITBIR as part of you or your child's participation in this research study will be de-identified—i.e., you and/or your child's name will be separated from the data. However, since this institution and others submitting data to FITBIR will still retain individually identifying information related to the data provided, the NIH has issued a legislatively authorized "Certificate of Confidentiality" to help FITBIR and participating institutions avoid being forced (e.g., by court subpoena) to disclose information that may identify you as an FITBIR participant in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings.

Finally, you should understand that we, the investigators, are also permitted to make voluntary disclosures with respect to information that is submitted to FITBIR, but do not plan to do so except in the event of severe threats to public health or safety. If, as part of your participation in this research study itself, we learn about serious harm to you, your child or someone else, we would take steps to prevent that harm including notifying appropriate authorities like the police or child welfare.

## APPENDIX IV: TECHNOLOGY READINESS LEVELS AND KNOWLEDGE READINESS LEVELS

**Technology Readiness Levels (TRLs):** TRLs are used to categorize the product maturity of materiel solutions. The DoD’s Technology Readiness Assessment (TRA) Deskbook, is a reference for systematic assessment of technical maturity of relevant materiel solutions. For biomedical applications, Biomedical TRL definitions and descriptions have been developed which account for regulatory context for technology maturity and *intended context of use*. Information on Biomedical TRLs can be found in Appendix E of the DoD TRA Deskbook (July 2009, <https://apps.dtic.mil/docs/citations/ADA524200>).

**Knowledge Readiness Levels (KRLs):** The scientific maturity of knowledge products resulting from biomedical research are not assessed in the same manner as materiel solutions. At the request of the U.S. Army Medical Research and Development Command, the Rand Corporation developed and released a framework to assess the relative scientific maturity of knowledge products. This process is described in a 2019 Rand Corporation Report ([https://www.rand.org/pubs/research\\_reports/RR2127.html](https://www.rand.org/pubs/research_reports/RR2127.html)). The figures below represent a quick reference guide for assessing KRLs for knowledge products.



## Step 2: Determine the Knowledge Readiness Level (KRL)

